Celgene International Sárl Release: REVLIMID(R) Receives Preliminary Positive Recommendation from National Institute for Clinical Excellence (NICE) And National Health Service in England and Wales

BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (Nasdaq:CELG): Celgene International Sàrl (Nasdaq:CELG) today announced that the company has received a preliminary positive recommendation from NICE for the use of REVLIMID in the NHS in England and Wales. The recommendation specifies the use of REVLIMID, in combination with dexamethasone, as an option for the treatment of patients with multiple myeloma who have received two or more prior therapies.